-
Article
Open AccessUncoupling neuronal death and dysfunction in Drosophila models of neurodegenerative disease
Common neurodegenerative proteinopathies, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), are characterized by the misfolding and aggregation of toxic protein species, including the amyloid beta...
-
Article
Open AccessDiscovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing
Whole-exome sequencing (WES) has been successful in identifying genes that cause familial Parkinson’s disease (PD). However, until now this approach has not been deployed to study large cohorts of unrelated pa...
-
Article
Open AccessThe global prevalence ptxP3 lineage of Bordetella pertussis was rare in young children with the co-purified aPV vaccination: a 5 years retrospective study
The global prevalent ptxP3 strains varies from about 10% to about 50% of circulating B. pertussis population in different areas of China.
-
Article
Open AccessA SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can provide an important treatment option to fight...
-
Article
Open AccessDelayed interval delivery in a quadruplet pregnancy: a case report and literature review
As the rate of multiple pregnancies increases, delayed interval delivery (DID) is increasingly being implemented to improve perinatal outcomes. But there are no international guidelines for DID in multiple pre...
-
Article
Open AccessPortable gas chromatography–mass spectrometry method for the in-field screening of organic pollutants in soil and water at pollution incidents
Environmental pollution incidents generate an emergency response from regulatory agencies to ensure that the impact on the environment is minimised. Knowing what pollutants are present provides important intel...
-
Article
Open AccessLong-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study
HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report th...